Get started
Author

Pangke Yan

Observed names: Pang-ke YAN, Pang-ke Yan, Pang‐ke Yan, Yan, Pangke
ORCID: 0009-0006-0626-4148
Observed ORCID: 0009-0006-0626-4148
OpenAlex ID: A5054635131
Mass balance, pharmacokinetics and pharmacodynamics of intravenous HSK3486, a novel anaesthetic, administered to healthy subjects
2020 · Yicong Bian, Hua Zhang, et al. · British Journal of Clinical Pharmacology · 162
Safety, Pharmacokinetics, and Pharmacodynamics of a Single Bolus of the γ-aminobutyric Acid (GABA) Receptor Potentiator HSK3486 in Healthy Chinese Elderly and Non-elderly
2021 · Xiaojiao Li, Deming Yang, et al. · Frontiers in Pharmacology · 94
PDF
Oral Delivery of Propofol with Methoxymethylphosphonic Acid as the Delivery Vehicle
2017 · Yonggang Wei, Guanpeng Qiu, et al. · Journal of Medicinal Chemistry · 64
Comparison of the Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A Multicenter, Randomized, Double-blind, Controlled, Phase 3 Noninferiority Trial
2023 · Tong J. Gan, Todd Bertoch, et al. · Anesthesiology · 56
PDF
Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes
2020 · Chen Zhang, Fei Ye, et al. · Journal of Medicinal Chemistry · 55
Population pharmacokinetic/pharmacodynamic modeling and exposure-response analysis of ciprofol in the induction and maintenance of general anesthesia in patients undergoing elective surgery: A prospective dose optimization study
2023 · Lu Liu, Kun Wang, et al. · Journal of Clinical Anesthesia · 41
The Immunosuppressant Cyclosporin A Antagonizes Human Formyl Peptide Receptor through Inhibition of Cognate Ligand Binding
2006 · Pangke Yan, Masakatsu Nanamori, et al. · The Journal of Immunology · 40
PDF
Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function
2023 · Jun Tao, Shuaibing Liu, et al. · Frontiers in Pharmacology · 22
PDF
Abstract CT128: Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies
2023 · Jianyong Li, Wei Xu, et al. · Cancer Research · 21
Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment
2022 · Yue Hu, Xiaojiao Li, et al. · Annals of Medicine · 17
Pharmacokinetics and exposure–safety relationship of ciprofol for sedation in mechanically ventilated patients in the intensive care unit
2024 · Lu Liu, Kun Wang, et al. · CPT Pharmacometrics & Systems Pharmacology · 15
Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions
2022 · Shuai‐bing Liu, Xia Yao, et al. · British Journal of Clinical Pharmacology · 14
SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models
2014 · Pang-ke Yan, Li-na Zhang, et al. · Acta Pharmacologica Sinica · 13
PDF
Development of a homogeneous calcium mobilization assay for high throughput screening of mas-related gene receptor agonists
2007 · Rui ZHANG, Pang-ke YAN, et al. · Acta Pharmacologica Sinica · 12
Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, phase 3 trial
2024 · Leili Gao, Fang Bian, et al. · Diabetes Obesity and Metabolism · 7
PDF
Model informed drug development: HSK21542 PBPK model supporting dose decisions in specific populations
2024 · Miao Zhang, Zihan Lei, et al. · European Journal of Pharmaceutical Sciences · 6
Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model
2023 · Miao Zhang, Shudong Zhang, et al. · European Journal of Pharmaceutical Sciences · 5
Abstract LB262: HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer
2023 · Ju Wang, Meilin Qian, et al. · Cancer Research · 5
Abstract 7146: HSK39775: A USP1 inhibitor for the treatment of cancers with homologous recombination deficiencies
2024 · Jun Xu, Yangguang Li, et al. · Cancer Research · 4
New Tricyclic γ-Aminobutyric Acid Analogue HSK16149: A Ca 2+ Channel α 2 -δ Ligand for Treating Neuropathic Pain
2025 · Zongjun Shi, Lei Chen, et al. · ACS Medicinal Chemistry Letters · 3
Abstract 4534: HSK40495, a highly selective PARP1 inhibitor with improved hematopoietic safety for the treatment of HRD cancers
2024 · Fan Li, Xiaoli Gou, et al. · Cancer Research · 2
Effects of Cipepofol on Cardiac Depolarization and Repolarization in Healthy Subjects: A Single-Center, Randomized, Placebo and Positive-Controlled Thorough QT Study
2026 · Robert Kleiman, Todd Rudo, et al. · Drug Design Development and Therapy · 1
PDF
Abstract LB014: HSK46256, a highly selective and brain penetrable PARP1 inhibitor for the treatment of HRD cancers
2025 · Fan Li, Haisco Pharmaceutical Group, et al. · Cancer Research · 1
Abstract 402: BCL6 degrader with novel CRBN ligand demonstrates promising selectivity and preclinical efficacy alone or in combination with BCL2 inhibitor
2025 · Jun Xu, Yangguang Li, et al. · Cancer Research · 1
Abstract 6062: Potent and orally bioavailable BCL6 protein degraders demonstrate efficacy in pre-clinical models of diffuse large B-cell lymphoma (DLBCL)
2024 · Jun Xu, Yangguang Li, et al. · Cancer Research · 1
Works count: 39
Citation count: 662
H-index: 13
I10-index: 14
Year
Topic
Type